PillRx only · Capsule · Oral
Asprin And Extended-Release Dipyridamole
Aspirin + Dipyridamole
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.564
Latest avg · Jul 22, 2026
-7%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
70
Rx · 2026 Q1
5.2K
Units dispensed
2
Quarters · since 2025 Q4
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc., USA | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jun 29, 2022RECALLRecall (Class III): Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark P…
Failed Tablet/Capsule Specification : Capsule breakage — Recalling firm: Glenmark Pharmaceuticals Inc., USA — USA Nationwide